NCT06810882 Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy
| NCT ID | NCT06810882 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Ondansetron |
| Study Type | INTERVENTIONAL |
| Enrollment | 482 participants |
| Start Date | 2025-02-16 |
| Primary Completion | 2027-02-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 482 participants in total. It began in 2025-02-16 with a primary completion date of 2027-02-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective randomized non-inferiority study will be conducted to compare the analgesic anti-emetic effects of intravenous ondansetron versus perineural ondansetron in patients undergoing laparoscopic sleeve gastrectomy.
Eligibility Criteria
Inclusion Criteria: * Patients of either sex * American Society Anesthesiologists physical (ASA) status II-III * age between 18-65 years old * Body mass index (BMI) \>35 kg/m2 with comorbidity or \> 40 kg/m2 -- undergoing laparoscopic sleeve gastrectomy with intraoperative surgeon performed laparoscopic paragastric autonomic neural blockade.. Exclusion Criteria: * Allergy to experimental drugs. * Known to have long QT, previous history of postoperative nausea and vomiting * Abuse of alcohol, analgesia, or sedative antidepressant drugs * Chronic pain disorders * History of previous upper gastrointestinal system surgery, those with surgery-related complications during or after surgery. * Liver or kidney failure * Performance of concomitant procedures in addition to laparoscopic sleeve gastrectomy * Anesthetic complications that may alter the postoperative management protocol.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06810882 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Ondansetron. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06810882 currently recruiting?
Yes, NCT06810882 is actively recruiting participants. Contact the research team at osamarehab@med.tanta.edu.eg for enrollment information.
Where is the NCT06810882 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06810882 clinical trial?
NCT06810882 is sponsored by Tanta University. The trial plans to enroll 482 participants.